DIREVO announces validation of bestMab
New approach for the optimization of therapeutic antibodies generates optiMIRA, an enhanced version of Adalimumab (Humira)
"This is a major technical and commercial breakthrough in antibody engineering that has the potential to significantly enhance antibody drug development," said Dr. Thomas von Rüden, CEO of DIREVO. "I am very proud of our interdisciplinary team of scientists and technicians who have made this important contribution to a key area of antibody R&D."
DIREVO will use bestMab(TM) as a proprietary cornerstone of its therapeutic antibody platform. Based on bestMab(TM), DIREVO will generate superior 2nd generation antibodies and improve success rates of antibodies in development, both for internal proprietary programs and through partnerships with the pharmaceutical and biopharmaceutical industries.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous